Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ConductScience Library
OpenNo account needed
One record for each comparison of two groups in a trial that posted counts to ClinicalTrials.gov: an outcome, serious adverse events or deaths from any cause. ConductScience calculates each group's risk, the risk difference, risk ratio, odds ratio and number needed to treat or harm from the counts in CTTI's AACT copy of 23 Mar 2026, with 95% intervals.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Try searching
Most participants first33,758 with no events in either group come last1 to 20 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Flublok Recipients vs SD-IIV Recipients: deaths from any cause | 352 of 632,962 501 of 997,366 | 0.0 points -0.0 to 0.0 | 1,630,328 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Exposed Cohort: Vaccinated With Trumenba + MenACWY vs Non-Exposed Cohort: Vaccinated With MenACWY Only: Number of Participants With Chlamydial Infection After at Least 1 Dose of Trumenba to Determine VE | 1,138 of 214,552 7,261 of 1,092,826 | -0.1 points -0.2 to -0.1 | 1,307,378 | NCT05873751 A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States. |
| Exposed Cohort: Vaccinated With Trumenba + MenACWY vs Non-Exposed Cohort: Vaccinated With MenACWY Only: Number of Participants With Gonococcal Infection After at Least 1 Dose of Trumenba to Determine Vaccine Effectiveness (VE) | 316 of 214,552 2,327 of 1,092,826 | -0.1 points -0.1 to -0.0 | 1,307,378 | NCT05873751 A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States. |
| Exposed Cohort: Vaccinated With Trumenba + MenACWY vs Non-Exposed Cohort: Vaccinated With MenACWY Only: Number of Participants With Chlamydial Infection After at Least 2 Doses of Trumenba to Determine VE | 584 of 92,661 7,261 of 1,092,826 | -0.0 points -0.1 to 0.0 | 1,185,487 | NCT05873751 A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States. |
| Exposed Cohort: Vaccinated With Trumenba + MenACWY vs Non-Exposed Cohort: Vaccinated With MenACWY Only: Number of Participants With Gonococcal Infection After at Least 2 Doses of Trumenba to Determine VE | 165 of 92,661 2,327 of 1,092,826 | -0.0 points -0.1 to -0.0 | 1,185,487 | NCT05873751 A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States. |
| Participants Exposed to OACs vs Participants Unexposed to OACs: Number of Participants Who Were New Users of OAC and VKA | 421,313 of 601,998 0 of 395,461 | 70.0 points 69.9 to 70.1 | 997,459 | NCT05838664 A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old Hospitalized With Cardio-respiratory Events | 133 of 353,562 208 of 601,514 | 0.0 points -0.0 to 0.0 | 955,076 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old Hospitalized With Community-acquired Pneumonia | 37 of 353,562 49 of 601,514 | 0.0 points -0.0 to 0.0 | 955,076 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old Hospitalized With PCR-confirmed Influenza | 48 of 353,562 88 of 601,514 | -0.0 points -0.0 to 0.0 | 955,076 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old With All-Cause Mortality | 66 of 353,562 79 of 601,514 | 0.0 points 0.0 to 0.0 | 955,076 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza B Tests | 146 of 353,562 231 of 601,514 | 0.0 points -0.0 to 0.0 | 955,076 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza Tests | 827 of 353,562 1,510 of 601,514 | -0.0 points -0.0 to 0.0 | 955,076 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old With All-Cause-Hospitalizations | 1,858 of 353,562 2,950 of 601,514 | 0.0 points 0.0 to 0.1 | 955,076 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza A Tests | 682 of 353,562 1,282 of 601,514 | -0.0 points -0.0 to -0.0 | 955,076 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old With Influenza-Like Illness (ILI) | 2,904 of 353,562 5,434 of 601,514 | -0.1 points -0.1 to -0.0 | 955,076 | NCT03694392 Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years |
| Participants Exposed to OACs vs Participants Unexposed to OACs: Number of Participants With Atleast One Visit to Nursing Home in Non-valvular AF Participants Exposed to OAC and Unexposed to OAC | 16,170 of 485,646 31,493 of 332,236 | -6.1 points -6.3 to -6.0 | 817,882 | NCT05838664 A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France |
| Participants Exposed to OACs vs Participants Unexposed to OACs: Number of Participants Who Were Polymedicated in Non-valvular AF Participants Exposed to OAC and Unexposed to OAC | 408,403 of 485,646 291,508 of 332,236 | -3.6 points -3.8 to -3.5 | 817,882 | NCT05838664 A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France |
| Participants Exposed to OACs vs Participants Unexposed to OACs: Number of Participants Who Received Complimentary Universal Health Care (CMU-c) in Non-valvular AF Participants Exposed to OAC and Unexposed to OAC | 12,819 of 485,646 10,198 of 332,236 | -0.4 points -0.5 to -0.4 | 817,882 | NCT05838664 A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France |
| Participants Exposed to OACs vs Participants Unexposed to OACs: Number of Participants Who Received Aid for Complementary Health Care (ACS) for Elderly Participants in Non-valvular AF Participants Exposed to OAC and Unexposed to OAC | 10,444 of 485,646 8,698 of 332,236 | -0.5 points -0.5 to -0.4 | 817,882 | NCT05838664 A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France |
| Participants Exposed to OACs vs Participants Unexposed to OACs: Number of Participants With Contraindications to OAC at Index Date in Non-valvular AF Participants Exposed to OAC and Unexposed to OAC | 49,478 of 485,646 86,646 of 332,236 | -15.9 points -16.1 to -15.7 | 817,882 | NCT05838664 A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03694392-deaths",
"title": "Flublok Recipients vs SD-IIV Recipients: deaths from any cause",
"summary": "352 of 632962 against 501 of 997366; risk difference 0.0 points, 95% interval -0.0 to 0.0; NCT03694392, Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years",
"record": "/library/comparisons/NCT03694392-deaths",
"nct_id": "NCT03694392",
"kind": "deaths",
"participants": 1630328,
"risk_difference": {
"value": 0.00005379241390628304,
"lower": -0.000017967762108580493,
"upper": 0.0001280617273885157
},
"group_1": "352 of 632,962",
"group_2": "501 of 997,366",
"difference": "0.0 points",
"interval": "-0.0 to 0.0",
"trial_title": "Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years"
},
{
"id": "NCT05873751-16c2f2b2",
"title": "Exposed Cohort: Vaccinated With Trumenba + MenACWY vs Non-Exposed Cohort: Vaccinated With MenACWY Only: Number of Participants With Chlamydial Infection After at Least 1 Dose of Trumenba to Determine VE",
"summary": "1138 of 214552 against 7261 of 1092826; risk difference -0.1 points, 95% interval -0.2 to -0.1; NCT05873751, A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.",
"record": "/library/comparisons/NCT05873751-16c2f2b2",
"nct_id": "NCT05873751",
"kind": "outcome",
"participants": 1307378,
"risk_difference": {
"value": -0.0013401661578708538,
"lower": -0.0016761819324575106,
"upper": -0.0009898187522996756
},
"group_1": "1,138 of 214,552",
"group_2": "7,261 of 1,092,826",
"difference": "-0.1 points",
"interval": "-0.2 to -0.1",
"trial_title": "A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States."
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=2",
"request_id": "8Zbu5QRKIFHAE-HS"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant